Connect with us

Industry

‘Landmark’ ruling gives hope for UK CBD flower businesses

The UK Court of Appeal does not consider hemp flower with a THC content below 0.2% as ‘a narcotic drug’.

Published

on

close up of woman holding cannabis flower
The Court of Appeal has made it clear that it does not consider hemp flower with a THC content below 0.2% as ‘a narcotic drug’. Photo: Elsa Olofsson/Unsplash
Listen to this article

Via Business of Cannabis 

A ‘landmark’ Court of Appeal ruling in the UK has set a new legal precedent for businesses in the UK importing and selling CBD or low-THC hemp flower.

Crucially, the Court of Appeal has made it clear that it does not consider hemp flower with a THC content below 0.2% as ‘a narcotic drug’.

Despite this, due to the timing and complexity of the case, this is far from the definitive free pass to import and sell low-THC flower that has recently been seen in France.

As Robert Jappie, Life Sciences Partner at Fieldfisher, explained to Business of Cannabis: “It doesn’t give the green light for these businesses to carry on and openly trade, but, at the same time, I think it substantially reduces their risk of criminal prosecution.”

The case

Uncle Herb, an online UK CBD flower retailer run by Eleanor Margiotta and Dean Taylor, had a batch of flower imported from Italy intercepted by customs in September 2019.

A year later, the owners were arrested and charged with ‘being knowingly concerned in the fraudulent evasion of a prohibition on the importation of goods’, as well as ‘being concerned in the supply of cannabis to another’, effectively charging them as drug dealers.

The charges, which were reportedly ‘devastating’ to the owners, effectively driving the retailer out of business, were challenged by Ms Margiotta, who is understood to have represented herself in court after initially being refused representation.

UK police forces class all cannabis sativa flower, regardless of THC content, as a controlled substance, an element of the Misuse of Drugs Act which has long hindered the CBD and hemp industries.

Despite this, Ms Margiotta successfully argued that under EU law, which superseded UK law at the time, it was unlawful to place any restriction on the movement of cannabis sativa, or hemp, with a THC level of below 0.2%, as it was an agricultural product.

Thus, the Misuse of Drugs Act was found to be a restriction on the movement of hemp, and the Crown Court ruled no offence had been committed.

The Crown Prosecution Service (CPS) then appealed this decision, meaning the decision was taken to the Court of Appeal, the highest court in the country, where the decision was upheld.

As Mr Jappie explained: “The judgement has now established case precedent. You wouldn’t normally be able to rely just on a Crown Court decision, but the fact that it’s gone up to the Court of Appeal and has been reviewed and reaffirmed means that it is now case precedent that other companies and other individuals can rely on.”

Implications and limitations 

Key to Ms Margiotta’s success was the fact that the trading took place before the UK officially left the EU on January 31, 2020, when laws regarding the freedom of movement of goods across the EU still applied.

This means that cannabis businesses that have been or are currently being investigated for activity after the cut-off date ‘will not be able to make the same argument’.

Mr Jappie explained: “The UK is not a member of the EU. So, freedom of movement of people, freedom of movement of capital, freedom of movement of goods does not apply, and that is indisputable.”

However, for those businesses in a similar position which have been charged or are being investigated for infringements prior to the cut-off date, they can now argue with some confidence that ‘they should never have been found guilty or should never have pleaded guilty, because of this new judgement’.

Potentially powerful ruling 

While he cautioned CBD sellers not to get overexcited, or to take this as a sign that they can trade freely, Mr Jappie said he believed the ruling remained ‘potentially very powerful’.

He added the ‘fact is the courts confirmed CBD flower does not have sufficient THC to be considered a narcotic product and, therefore, the reality is the government shouldn’t be controlling it as a narcotic’.

“I think this will cause the CPS quite significant issues going forward in relation to similar cases. When making a decision on a charge, it’s a two-stage test. Is there sufficient evidence to secure a prosecution and is it in the public interest to prosecute? And if the product is deemed to not be a narcotic, and people aren’t getting high from it, then where’s the public interest in prosecuting these people as drug dealers?

“If I was currently under investigation or being prosecuted for CBD flower offences, I would be getting my lawyers to really aggressively push the CPS to review their position in light of this Court of Appeal judgement.

“The question has now been put by the Court of Appeal, why are we using narcotics legislation to prohibit a product that is not a narcotic?

“That is potentially very powerful. It could force the government to act and actually give some sort of declaration as to why they’re currently acting in this way, and it could result in a similar decision to France.”

This article was originally published by Business of Cannabis and is reprinted here with permission. 

Home » Industry » ‘Landmark’ ruling gives hope for UK CBD flower businesses

Trending